TNF and asthma: GA-C1 achieves the goal of treating asthma by reducing pulmonary inflammation and neutrophils, inhibiting the levels of TNF-α, IL-4, and IL-5, decreasing MUC5AC gene expression, and reducing the production of reactive oxygen species (ROS) [66].